645 research outputs found

    Sustainable Diagram on Food Waste Reduction Programs in Mitigating Carbon Footprint—a Loyola Marymount University Case Study

    Get PDF
    Food waste is an economic, social, and environmental problem with broad implication. The direct impacts from fossil fuel use, food waste rotting in landfills, water use, and transferring food waste create environmental stressors associated with climate change. Increasing methods to reduce food waste are becoming common practice across private sector as a tool to reduce economic cost and carbon footprint. This study aims to evaluate the food waste diversion efforts at Loyola Marymount University’s dining hall. The research approach examining Loyola Marymount dining halls’ sustainability efforts will be broken down into two separate stages: analyzing food waste data pre- and post-implementation of mitigation efforts, and diagramming the mitigation efforts including the composting, liquefying, and dehydrator processes. This study hopes to demonstrate how a university’s efforts to reduce food waste can contribute to the overall goal of sustainability. Using diagrams to relay findings, this study can serve as encouragement to LMU to continue and increase sustainability efforts, and as a model for other universities.https://digitalcommons.lmu.edu/cures_posters/1027/thumbnail.jp

    Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

    Get PDF
    Objectives Danusertib is a serine/threonine kinase inhibitor of multiple kinases, including aurora-A, B, and C. This explorative study aims to identify possible relationships between single nucleotide polymorphisms in genes coding for drug metabolizing enzymes and transporter proteins and clearance of danusertib, to clarify the interpatient variability in exposure. In addition, this study explores the relationship between target receptor polymorphisms and toxicity of danusertib. Methods For associations with clearance, 48 cancer patients treated in a phase I study were analyzed for ABCB1, ABCG2 and FMO3 polymorphisms. Association analyses between neutropenia and drug target receptors, including KDR, RET, FLT3, FLT4, AURKB and AURKA, were performed in 30 patients treated at recommended phase II dose-levels in three danusertib phase I or phase II trials. Results No relationships between danusertib clearance and drug metabolizing enzymes and transporter protein polymorphisms were found. Only, for the one patient with FMO3 18281AA polymorphism, a significantly higher clearance was noticed, compared to patients carrying at least 1 wild type allele. No effect of target receptor genotypes or haplotypes on neutropenia was observed. Conclusions As we did not find any major correlations between pharmacogenetic variability in the studied enzymes and transporters and pharmacokinetics nor toxicity, it is unlikely that danusertib is highly susceptible for pharmacogenetic variation. Therefore, no dosing alterations of danusertib are expected in the future, based on the polymorphisms studied. However, the relationship between FMO3 polymorphisms and clearance of danusertib warrants further research, as we could study only a small group of patients

    Over het multipel myeloom, het solitaire plasmocytoom en de macroglobulinaemie:klinische, histologische, biochemische en serologische waarnemingen

    Get PDF
    In 1949 zagen wij kort na elkaar twee patienten met multipel myeloom. Het viel ons toen op, dat het aspect van de myeloomcellen in het beenmergpunctaat van deze twee patienten sterk uiteenliep. In de loop van de volgende vijf jaren hebben wij gegevens verzameld over 47 patienten, van wie 40 lijdende waren aan de klassieke vorm van multipel myeloom en de overige 7 aan één van de varianten ervan, zoals het solitaire plasmocytoom en de macroglobulinaemie. .... Zie: Samenvattin

    The role of population PK-PD modelling in paediatric clinical research

    Get PDF
    Children differ from adults in their response to drugs. While this may be the result of changes in dose exposure (pharmacokinetics [PK]) and/or exposure response (pharmacodynamics [PD]) relationships, the magnitude of these changes may not be solely reflected by differences in body weight. As a consequence, dosing recommendations empirically derived from adults dosing regimens using linear extrapolations based on body weight, can result in therapeutic failure, occurrence of adverse effect or even fatalities. In order to define rational, patient-tailored dosing schemes, population PK-PD studies in children are needed. For the analysis of the data, population modelling using non-linear mixed effect modelling is the preferred tool since this approach allows for the analysis of sparse and unbalanced datasets. Additionally, it permits the exploration of the influence of different covariates such as body weight and age to explain the variability in drug response. Finally, using this approach, these PK-PD studies can be designed in the most efficient manner in order to obtain the maximum information on the PK-PD parameters with the highest precision. Once a population PK-PD model is developed, internal and external validations should be performed. If the model performs well in these validation procedures, model simulations can be used to define a dosing regimen, which in turn needs to be tested and challenged in a prospective clinical trial. This methodology will improve the efficacy/safety balance of dosing guidelines, which will be of benefit to the individual child
    corecore